{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-062544","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.392713+00:00","generated_at":"2026-06-01T19:13:46.776610+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Traws Pharma Q1 2024 net loss $5.0M; cash $16.4M, extended by $14M April raise","bullets":["Cash $16.4M at March 31, 2024; raised $14M in April from TPAV/OrbiMed, funding into Q4 2024.","Net loss $5.0M ($0.24/shr) vs $5.8M ($0.28/shr) in Q1 2023; R&D down to $1.9M from $4.1M.","Completed acquisition of Trawsfynydd and concurrent $14M private placement in April 2024.","Initiated Phase 1 dosing for COVID candidate ratutrelvir; last dose cohort for narazaciclib done.","Plans Phase 2 for influenza and COVID in H2 2024; topline data expected H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-062544","json":"https://secwatch.observer/filing/0001104659-24-062544.json","markdown":"https://secwatch.observer/filing/0001104659-24-062544.md","text":"https://secwatch.observer/filing/0001104659-24-062544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924062544/0001104659-24-062544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924062544/tm2414653d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T19:13:46.776610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87ef79ad6d1013e93d2058e247551340b0be388c","claim":"Traws Pharma, Inc. reported the first quarter of 2024 results: revenue fifty-six thousand dollars, net income $5.0 million, or $0.24 per share, EPS $0.24 per share.","evidence_excerpt":"Revenue was fifty-six thousand dollars for the first quarter of 2024, consistent with the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924062544/0001104659-24-062544-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"fifty-six thousand dollars"},{"label":"Net income","value":"$5.0 million, or $0.24 per share"},{"label":"EPS","value":"$0.24 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}